BlissBio Inc. Files for Hong Kong IPO to Advance Oncology-Focused ADC Pipeline
Hangzhou-based oncology-focused clinical-stage biotech BlissBio Inc. has filed for an initial public offering (IPO) with...
ADC / XDC
Hua Dong Medicine’s HDM2020 Gains NMPA Approval for Clinical Trials
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...
Bio-Thera Solutions Initiates Phase III Trial of BAT8006 for Platinum-Resistant Ovarian Cancer
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced the successful first patient dosing in its Phase III...
Lepu Biopharma Gains EMA Approval for MRG003 HNSCC Clinical Trial
China-based Lepu Biopharma Co., Ltd (HKG: 2157) announced that it has received approval from the...
Medilink Therapeutics’ YL201 Wins FDA Breakthrough Therapy Designation for SCLC
Suzhou-based Medilink Therapeutics announced that it has received Breakthrough Therapy Designation (BTD) from the US...
FDA Approves AstraZeneca’s Datopotamab deruxtecan for EGFR-Mutated NSCLC
The US Food and Drug Administration (FDA) this week approved Datopotamab deruxtecan (Dato-DXd), a TROP-2-targeted...
Hengrui Pharmaceuticals Wins NMPA Approval for Six Novel Solid Tumor Drugs
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clinical trial approvals from the...
Sichuan Huiyu’s CDCP1-Targeted ADC HY0001a Gets NMPA Clinical Trial Approval
China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) announced that it has received clinical trial...
MSD Initiates IDeate-Prostate01 Phase III Trial of Ifinatamab Deruxtecan for mCRPC
Merck, Sharp & Dohme (MSD, NYSE: MRK) this week announced the first patient dosing in...
GlycoT Therapeutics Partners with Innovent Biologics to Advance ADC Technology
US-based GlycoT Therapeutics LLC last week inked a license agreement with Innovent Biologics, Inc. (HKG:...
Shanghai Escugen and SunRock Biopharma Collaborate on First-in-Class CCR9-Targeted ADC
China-based Shanghai Escugen has partnered with Spain-headquartered SunRock Biopharma, S.L. to co – develop SRB123,...
Simcere and NextCure Forge Strategic Alliance to Co-Develop SIM0505 ADC for Solid Tumors
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming and US-headquartered NextCure, Inc. (NASDAQ:...
Escugen Partners with SovranBio to Accelerate Development of Antibody-Drug Conjugates
Shanghai Escugen, a China-based clinical-stage company specializing in innovative antibody-drug conjugate (ADC) development, announced a...
Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation
Japan-based Daiichi Sankyo (TYO: 4568) has registered a Phase I clinical trial on ClinicalTrials.gov for...
Hengrui Pharmaceuticals Launches Aiweida for HER2-Mutated NSCLC in China
China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the first commercial shipment of its...
Sanyou Biopharma Partners with Medicovestor to Advance Next-Gen ADCs
China-based Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced a strategic partnership with US-headquartered Medicovestor, Inc. to...
OBI Pharma Partners with TegMine to Develop Antibody-Drug Conjugates
Taiwan-based OBI Pharma announced a collaboration with San Francisco-based TegMine Therapeutics, Inc. to develop antibody-drug...
EU Approves Pfizer and Takeda’s Adcetris in Hodgkin Lymphoma Combination Regimen
Partners Pfizer (NYSE: PFE) and Takeda (TYO: 4502) announced that the European Commission (EC) has...
Biokin Pharma Enrolls First Patient in BL-M07D1 Phase III Trial for HER2 Low Breast Cancer
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced the enrollment of the first patient...
Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting
Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at...